Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors - A population-based study.
Khalaf KridinHenner ZirpelNoor MruwatRalf J LudwigDiamant ThaciPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Compared with TNFi, IL-23i and IL-17i are associated with decreased risk of several infectious diseases. These agents might be preferred in patients with susceptibility to infections.
Keyphrases